AMARIN CORP PLC\UK Excess Tax Benefit from Share-based Compensation, Financing Activities
AMARIN CORP PLC\UK (AMRN) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of -$641.00 thousand for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-08-06.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2015-08-06
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, financing activities for the quarter ending 2015-06-30 was -$89.00K, a 4550.00% decline year-over-year.
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, financing activities for the quarter ending 2015-03-31 was -$552.00K.
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-06-30 was $2.00K.
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-03-31 was -$1.00K.
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, financing activities for fiscal 2014 was -$2.30M.
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, financing activities for fiscal 2013 was -$361.00K, a 103.19% decline from fiscal 2012.
- AMARIN CORP PLC\UK excess tax benefit from share-based compensation, financing activities for fiscal 2012 was $11.33M.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|
| 2015-06-30 | -$89.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$641.00K 10-Q · filed 2015-08-06 | |
| 2015-03-31 | -$552.00K 10-Q · filed 2015-05-08 | ||
| 2014-12-31 | -$2.30M 10-K · filed 2015-03-03 | ||
| 2014-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $1.00K 10-Q · filed 2015-08-06 | |
| 2014-03-31 | -$1.00K 10-Q · filed 2015-05-08 | ||
| 2013-12-31 | -$361.00K 10-K · filed 2015-03-03 | ||
| 2012-12-31 | $11.33M 10-K · filed 2015-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |